The relationship of melatonin (MT) level, oxidative stress and inflammatory status with osteoporosis in the maintenance hemodialysis (MHD) of chronic renal failure was investigated. Ninety-four patients with chronic renal failure treated in Dezhou People's Hospital (Dezhoo, China) and receiving MHD for more than 3 months from May to April 2017 were selected and divided into the osteoporosis group (observation group, n=49) and the non-osteoporosis group (control group, n=45) based on whether osteoporosis was involved. The serum advanced oxidation protein products (AOPP), MT level and inflammatory factors [tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and IL-1] in patients were detected via enzyme-linked immunosorbent assay (ELISA). Moreover, the malondialdehyde (MDA) level in serum was detected via thibabituric acid (TBA) assay and the spinal bone mineral density (BMD) was detected using the total BMD testing instrument, followed by correlation analysis. The MT level in observation group was significantly lower than that in control group, but the levels of AOPP and MDA were significantly higher than those in control group (P<0.05). The levels of inflammatory factors (TNF-α, IL-6 and IL-1) in observation group were obviously higher than those in the control group (P<0.05). Besides, the spinal BMD and T-value in observation group were significantly lower than those in the control group (P<0.05). Pearson's correlation analysis showed that AOPP, MDA, TNF-α, IL-6 and IL-1 levels were negatively correlated with BMD, but MT was positively correlated with BMD (P<0.05). Osteoporosis occurs easily in MHD patients; oxidative stress and inflammatory degree are negatively correlated with osteoporosis, but MT is positively correlated with osteoporosis.

Chronic renal failure is a type of clinical syndrome originating from chronic renal diseases. The aim of the study was to investigate the effect of astrogaloside on the inflammation and immunity of renal failure patients receiving maintenance dialysis. We randomly selected 92 renal failure patients receiving maintenance dialysis who were admitted to hospital for treatment between May, 2015 and April, 2016. Patients were randomly divided into the control (n=46) and observation (n=46) groups. Patients in the control group received the regular dialysis plus the basic treatment in Western medicine, while in the observation group, patients additionally received astrogaloside via intravenous injection as treatment. We compared the clinical efficacy of patients between the two groups, residual renal function (RRF), changes in urine volume, variations in inflammatory indicators [C-reaction protein (CRP), interleukin-6 (IL-6), IL-17, and tumor necrosis factor-α (TNF-α)] before and after treatment, and the levels of the thymus-dependent lymphocyte (T cells) subgroup (CD3+, CD4+, CD8+ and CD4+/CD8+) in the immune system of patients after treatment. In the observation group, the total effective rate was significantly higher than that in the control group (P<0.05). After 6 months, RRF and the urine volume of patients in the two groups were decreased when compared with the levels before treatment, and the decreasing rates of RRF and urine volume in the observation group were significantly lower than those in the control group (P<0.05). After treatment, the levels of human serum C reaction protein (hs-CRP), IL-6, IL-17 and TNF-α in the two groups were lower than those before treatment, and the decrease in the observation group was more significant than that in the control group (P<0.05). Following treatment, the levels of CD3+, CD4+ and CD4+/CD8+ in the observation group were higher than those in the control group, and the level of CD8+ was lower than that in the control group (P<0.05). In conclusion, astrogaloside can delay the decrease in RRF of renal failure patients receiving the maintenance dialysis, ameliorate the inflammatory responses, and enhance the immune function, thereby increasing the disease resistance of patients and improving the clinical symptoms.